Fukuyama congenital muscular dystrophy (FCMD) is a type of muscular dystrophy that is present at birth and affects the Japanese population almost exclusively. The condition’s primary symptoms are progressive weakness in skeletal muscles and impaired brain development.
There currently is no cure for FCMD, but medical management can slow the disease’s progression and improve patients’ quality of life.
Adaptive devices such as long leg braces can improve standing posture. Wheelchairs can increase mobility.
Respiratory function should be assessed regularly in individuals with advanced FCMD and who are older than 10.
Non-invasive ventilation can relieve respiratory distress, especially at night.
FCMD patients frequently develop respiratory tract infections, which must be treated immediately. These infections are the most common cause of hospital admissions and death in FCMD patients.
Caloric intake and nutritional status should be assessed regularly. A feeding tube (gastrostomy) may be necessary to ensure adequate caloric intake.
Patients who experience seizures should be clinically evaluated every three months. An electroencephalogram (a procedure that measures the electrical activity in the brain) should be performed every six months. Anticonvulsant medications can help control seizures.
Last updated: Aug. 21, 2019
Muscular Dystrophy News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.